低剂量维生素D-钙联合补充剂（钙尔奇D）改善女性良性阵发性位置性眩晕成功复位后残余头晕：一项8周回顾性研究
Improvement of residual dizziness associated with a low-dose vitamin D-calcium combination (Caltrate D) supplementation in female patients with benign paroxysmal positional vertigo after successful repositioning: an 8-week retrospective study.
文献信息
| PMID | 42827651 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Weiwei Han |
| 作者单位 | Department of Rehabilitation, Ningbo No. 2 Hospital, Wenzhou Medical University, Ningbo, Zhejiang, China. |
| 期刊 | Frontiers in nutrition |
| SCI 分区 | Q1 |
| IF | 6.1 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 耳科 |
中文摘要
背景： 残余头晕（RD）是良性阵发性位置性眩晕（BPPV）成功行耳石复位手法（CRP）后常见且令人衰弱的症状。目前尚无有效的药物治疗。我们先前的研究发现低血清25-羟基维生素D[25(OH)D]是RD的独立危险因素。因此，本研究评估了8周钙尔奇D补充是否与RD改善相关。
方法： 纳入原发性BPPV女性患者，这些患者在CRP成功后第7天仍主诉RD，且血清25(OH)D < 20 ng/mL。服用钙尔奇D 8周的患者组成治疗组，而未接受维生素D或钙补充的患者作为对照组。主要结局是4周和8周时头晕障碍量表（DHI）总分的改善率。次要结局包括RD持续时间。
结果： 治疗组43例和对照组48例完成了研究。在4周和8周时，治疗组的DHI改善率显著高于对照组（分别为56.2% ± 10.8% vs. 44.4% ± 11.8%和77.6% ± 6.34% vs. 66.9% ± 9.8%；均p < 0.001）。治疗组的中位RD持续时间也显著短于对照组（12天，IQR 7-18 vs. 19天，IQR 12-24；p = 0.007）。
结论： 在这项针对成功CRP后伴有RD和维生素D缺乏的女性BPPV患者的回顾性队列中，8周钙尔奇D补充与DHI评分改善和RD持续时间缩短相关。需要前瞻性研究来证实这些观察结果。
英文摘要
BACKGROUND: Residual dizziness (RD) is a common and debilitating symptom following successful canalith repositioning procedure (CRP) for benign paroxysmal positional vertigo (BPPV). Currently, no effective pharmacological treatment exists for this condition. Our previous work identified low serum 25-hydroxyvitamin D [25(OH)D] as an independent risk factor for RD. This study therefore evaluated whether 8-week supplementation with Caltrate D was associated with improvement in RD.
METHODS: Female patients with primary BPPV who achieved successful CRP but still complained of RD at day 7 post-CRP and had serum 25(OH)D < 20 ng/mL were enrolled. Patients who took Caltrate D for 8 weeks formed the treatment group, while those who received no vitamin D or calcium supplementation served as the control group. The primary outcome was the improvement rate of the Dizziness Handicap Inventory (DHI) total score at 4 and 8 weeks. Secondary outcomes included duration of RD.
RESULTS: Forty-three patients in the treatment group and 48 in the control group completed the study. At 4 and 8 weeks, DHI improvement rates were significantly higher in the treatment group than in the control group (56.2% ± 10.8% vs. 44.4% ± 11.8 and 77.6% ± 6.34% vs. 66.9% ± 9.8%, respectively; both p < 0.001). The median RD duration was also significantly shorter in the treatment group (12 days, IQR 7-18 vs. 19 days, IQR 12-24; p = 0.007) than in the control group.
CONCLUSION: In this retrospective cohort of female BPPV patients with RD and vitamin D deficiency after successful CRP, 8-week Caltrate D supplementation was associated with improvement in DHI score and shortening of RD duration. Prospective studies are warranted to confirm these observations.